Summary of the haemorrhagic risk of eight trials that tested dual versus single antiplatelet agent
| Trials | Antiplatelet agent | Major or moderate haemorrhage | Haemorrhagic event | Haemorrhagic complication | Minor haemorrhage |
|---|---|---|---|---|---|
| CURE | Clopidogrel 300 mg load+ various doses of ASA (%) for 3–12 months | 3.7 | 2.1 | ||
| ASA 75–325 mg (%) for 3–12 months | 2.7 | 1.8 | |||
| SPS3 | Clopidogrel 75 mg+ ASA 325 mg for 8 years (%) | 2.1 | |||
| ASA 325 mg for 8 years (%) | 1.1 | ||||
| CHARISMA | Clopidogrel 75 mg+ASA 75–162 mg for 28 months | 2.1 | |||
| ASA 75–162 mg for 28 months | 1.3 | ||||
| MATCH | Clopidogrel 75 mg+ ASA75 mg (%) for 18 months | 8.1 | |||
| Clopidogrel 75 mg for 18 months | 3.5 | ||||
| CLAIR | Clopidogrel 300 loading, then 75 mg+ ASA 75–160 mg for 7 days | 2 cases | |||
| ASA 75–160 mg for 7 days | none | ||||
| Korean | Cilostazol 100 mg twice daily+ ASA 75–160 mg for 7 months (%) | 0.9 | |||
| Clopidogrel 75 mg+ ASA 75–160 mg for 7 months (%) | 2.6 | ||||
| SAMMPRIS | Recent stroke or TIA (within 30 days) attributable to severe stenosis (70–99%) of a major intracranial artery, clopidogrel 75 mg+ASA 325 mg for 90 days | 1.8 | |||
| CARESS | Clopidogrel 300 mg loading followed by 75 mg for 7 days | 2 of 52 cases | |||
| ASA 75 mg for 7 days | none | ||||
| CHANCE | Clopidogrel 300 mg load followed by 75 mg for 90 days +ASA 75 mg for the initial 21 days (%) | 2.3 | |||
| ASA 75 mg for the initial 21 days (%) | 1.6 | ||||
ASA, American Stroke Association; CARESS, Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis; CHANCE, Clopidogrel in High-Risk Patients with Acute Nondisabling Ischemic Cerebrovascular Events; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; CURE, Clopidogrel in the Unstable Angina to Prevent Recurrent Events; SPS3, Secondary Prevention of Small Subcortical Strokes; TIA, transient ischaemic attack.